Understanding VMAT2 Inhibitors for Tardive Dyskinesia
Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements such as twitching, thrusting, shaking, and grimacing. These symptoms can range from mild and unnoticeable to severe enough to disrupt daily activities and quality of life. For patients whose symptoms are bothersome, medications known as VMAT2 inhibitors offer an option to reduce symptom severity.
This article outlines what VMAT2 inhibitors are, how they work, who qualifies for them, and how healthcare providers monitor their effectiveness, based on insights from movement disorders neurologist Dr. Adam Margolius of the Cleveland Clinic.
Note: This informational overview was prepared with AI assistance from source material provided by Cleveland Clinic.
What Are VMAT2 Inhibitors and How Do They Work?
VMAT2 inhibitors are medications designed to make involuntary movements from tardive dyskinesia less severe by calming overactive brain signals.
Tardive dyskinesia most frequently results from taking dopamine-blocking medications (dopamine antagonists). Researchers believe that blocking this neurotransmitter can cause dopamine receptors to become extra sensitive in some people, disrupting the brain's movement-control circuits. VMAT2 inhibitors counteract this by reducing the amount of dopamine released between nerve cells, helping to calm TD symptoms.
While these medications do not eliminate symptoms completely or cure the condition, Dr. Margolius notes that they can significantly reduce movements and improve quality of life.
FDA-Approved Types
The U.S. Food and Drug Administration (FDA) has approved two VMAT2 inhibitors specifically for tardive dyskinesia:
- Deutetrabenazine (sold as Austedo or Austedo XR)
- Valbenazine (sold as Ingrezza)
Both drugs target and block a specific cellular protein called vesicular monoamine transporter 2 (VMAT2). Because they function similarly, selection often comes down to individual accessibility and affordability.
Note: Another VMAT2 inhibitor, tetrabenazine, was previously used more commonly for TD, but it lacks official FDA approval for this specific condition, making providers much more likely to prescribe deutetrabenazine or valbenazine.
Who Is a Candidate for VMAT2 Inhibitors?
Not everyone with tardive dyskinesia requires medication. Treatment suitability depends largely on whether the movements are bothersome and interfere with normal daily life.
Before recommending a VMAT2 inhibitor, healthcare providers typically take several steps:
- Confirm the diagnosis: Providers must ensure the condition is actually TD, as other disorders like Parkinson's disease, Huntington's disease, and stroke can present with similar symptoms.
- Evaluate severity: If movements do not affect the patient's quality of life, providers may choose to monitor them rather than treat them.
- Address triggers: Factors like anxiety, stress, or lack of sleep can worsen TD symptoms.
- Adjust other medications: When possible, switching to a different psychiatric medication can positively affect TD. However, patients should always consult their healthcare provider and never stop or change psychiatric medications on their own.
When VMAT2 Inhibitors May Not Be Appropriate
These medications are not a good fit for everyone. A healthcare provider may avoid them if a patient is taking certain conflicting medications or has (or is at high risk for):
- Cardiac arrhythmia
- Parkinson's-like symptoms (parkinsonism)
- Severe liver conditions
- Significant psychiatric concerns
How Effectiveness Is Monitored
When a patient starts a VMAT2 inhibitor, ongoing monitoring helps the care team decide whether to adjust the dosage or alter the treatment plan.
Providers evaluate progress using two primary measures:
- Clinical Assessment: Providers use a 12-item assessment called the Abnormal Involuntary Movement Scale (AIMS) to gauge movement severity in the face, torso, arms, and legs.
- Patient Perception: According to Dr. Margolius, the patient's personal experience is equally—if not more—important. If a patient feels the medication improves their quality of life, that perspective guides treatment decisions, even if objective physical movements appear similar to prior evaluations.
Because VMAT2 inhibitors are relatively new treatments introduced within the last decade, many individuals with tardive dyskinesia may not realize that targeted therapeutic options exist.